A recent survey conducted by the Duke University Robert J. Margolis, MD, Center for Health Policy and the National Pharmaceutical Council suggests that interest in value-based contracts may have been greater than previously thought.
The study, which was published in the American Journal of Managed Care, surveyed payers and biopharmaceutical companies that reported inking 100 value-based contracts between 2014-17, though only one in four were publicly announced.
“The study, believed to [be] the first of its kind, focused on exploring the prevalence and characteristics of both public and non-public VBAs in order to better understand current activity in value-based contracting,” NPC said in a release.
To read the study, click here.
